Answer
In patients with metastatic melanoma, vemurafenib’s population elimination half-life is estimated by population pharmacokinetic analysis at 51.6 hours, with individual estimates ranging from 29.8 to 119.5 hours at the 5th–95th percentiles.
Sources for this answer
- Zelboraf 240 mg Film-coated TabletsRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 30Document updated
Sources checked